AAAAAA
Results:
1-16
|
Results: 16
Authors:
Caroli-Bosc, FX
Van Laethem, JL
Michel, P
Gay, F
Hendlisz, A
Forget, F
Bleiberg, H
Citation: Fx. Caroli-bosc et al., A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas, EUR J CANC, 37(15), 2001, pp. 1828-1832
Authors:
Buecher, B
Bleiberg, H
Citation: B. Buecher et H. Bleiberg, Review article: non-systemic chemotherapy in the treatment of colorectal cancer - portal vein, hepatic arterial and intraperitoneal approaches, ALIM PHARM, 15(10), 2001, pp. 1527-1541
Authors:
Bensmaine, MA
Marty, M
de Gramont, A
Brienza, S
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients, BR J CANC, 85(4), 2001, pp. 509-517
Authors:
Van den Neste, E
de Valeriola, D
Kerger, J
Bleiberg, H
Kusenda, Z
Brassinne, C
Bartholomeus, S
Selleslags, J
Hennebert, P
Wythouck, H
Cazenave, I
Lefresne-Soulas, F
Piccart, M
Citation: E. Van Den Neste et al., A Phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors, CLIN CANC R, 6(1), 2000, pp. 64-71
Authors:
Bleiberg, H
Citation: H. Bleiberg, A new class of antiemetics: the NK-1 receptor antagonists, CURR OPIN O, 12(4), 2000, pp. 284-288
Authors:
Misset, JL
Bleiberg, H
Sutherland, W
Bekradda, M
Cvitkovic, E
Citation: Jl. Misset et al., Oxaliplatin clinical activity: a review, CR R ONC H, 35(2), 2000, pp. 75-93
Authors:
Bensmaine, MA
de Gramont, A
Brienza, S
Marty, M
Levi, F
Ducreux, M
Francois, E
Gamelin, E
Bleiberg, H
Bleuzen, P
Simon, J
Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/- folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients, EUR J CANC, 36(18), 2000, pp. 2335-2343
Authors:
Vanhoefer, U
Rougier, P
Wilke, H
Ducreux, MP
Lacave, AJ
Van Cutsem, E
Planker, M
Dos Santos, JG
Piedbois, P
Paillot, B
Bodenstein, H
Schmoll, HJ
Bleiberg, H
Nordlinger, B
Couvreur, ML
Baron, B
Wils, JA
Citation: U. Vanhoefer et al., Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group, J CL ONCOL, 18(14), 2000, pp. 2648-2657
Authors:
Bleiberg, H
Citation: H. Bleiberg, Adjuvant therapy in high-risk colon cancer, SEMIN ONCOL, 27(5), 2000, pp. 48-59
Authors:
Freyer, G
Rougier, P
Bugat, R
Droz, JP
Marty, M
Bleiberg, H
Mignard, D
Awad, L
Herait, P
Culine, S
Trillet-Lenoir, V
Citation: G. Freyer et al., Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure, BR J CANC, 83(4), 2000, pp. 431-437
Authors:
Bleiberg, H
Citation: H. Bleiberg, CPT-11 in gastrointestinal cancer, EUR J CANC, 35(3), 1999, pp. 371-379
Authors:
Van Cutsem, E
Cunningham, D
Huinink, WWT
Punt, CJA
Alexopoulos, CG
Dirix, L
Symann, M
Blijham, GH
Cholet, P
Fillet, G
Van Groeningen, C
Vannetzel, JM
Levi, F
Panagos, G
Unger, C
Wils, J
Cote, C
Blanc, C
Herait, P
Bleiberg, H
Citation: E. Van Cutsem et al., Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU), EUR J CANC, 35(1), 1999, pp. 54-59
Authors:
Brienza, S
Bensmaine, MA
Soulie, P
Louvet, C
Gamelin, E
Francois, E
Ducreux, M
Marty, M
Andre, T
de Braud, F
Bleiberg, H
Segal, V
Itzhaki, M
Cvitkovic, E
Citation: S. Brienza et al., Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program, ANN ONCOL, 10(11), 1999, pp. 1311-1316
Authors:
Primrose, JN
Bleiberg, H
Daniel, F
Van Belle, S
Mansi, JL
Seymour, M
Johnson, PW
Neoptolemos, JP
Baillet, M
Barker, K
Berrington, A
Brown, PD
Millar, AW
Lynch, KP
Citation: Jn. Primrose et al., Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen, BR J CANC, 79(3-4), 1999, pp. 509-514
Authors:
Bleiberg, H
Gerard, B
Citation: H. Bleiberg et B. Gerard, Current and new systemic treatment of hepatobiliary tumors, MALIGNANT LIVER TUMORS, 1999, pp. 85-95
Authors:
Bleiberg, H
Citation: H. Bleiberg, Can chemotherapy improve the quality of life of patients with advanced colorectal cancer?, EUROCANCER 98, 1998, pp. 85-87
Risultati:
1-16
|